Friday, September 4, 2015

Roth ups Sarepta Therapeutics price target to $50

Roth ups Sarepta Therapeutics price target to $50

August 26, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Sarepta Therapeutics (NASDAQ:SRPT) to $50 from $45 after the FDA set Feb 26 as the PDUFA date to consider approval of the company’s NDA for eteplirsen. The stock closed at $32.58 on Tuesday. Eteplirsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) amenable […]

Roth ups TearLab price target to $4

Roth ups TearLab price target to $4

August 7, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for TearLab (NASDAQ:TEAR; TSX:TLB) to $4 from $3 after the company posted a 27% jump in second quarter revenue. The stock closed at $2.48 on Friday. “TearLab delivered one of its stronger quarters in some time as 2Q revenues notably beat our projection driven by an […]

Analysts raise price target for LeMaitre Vascular

Analysts raise price target for LeMaitre Vascular

July 29, 2015 by · Leave a Comment 

Tweet Canaccord Genuity and Roth Capital Partners have raised their price targets for LeMaitre Vascular (NASDAQ:LMAT) to $14.50 from $13, and to $14 from $11, respectively, after the company set another record sales quarter. The stock closed at $11.24 on Tuesday. “We continue to view LeMaitre as one of the most undervalued small-cap stocks in […]

Roth starts Tracon Pharma at buy

Roth starts Tracon Pharma at buy

July 29, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Tracon Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $18 price target, calling the company an intriguing play in the $16-billion anti-VEGF market. The stock closed at $12.58 on Tuesday. Tracon is developing an antibody targeting the endoglin receptor. Endoglin is essential to the process of new blood […]

Roth upgrades IGI Labs to buy

Roth upgrades IGI Labs to buy

July 24, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded IGI Laboratories (NYSE MKT:IG) to “buy” from “neutral” and raised its price target to $11 from $7, saying 2016 could be a breakout year. The stock closed at $6.78 on Thursday. “The impetus for our upgrade is stabilization of the econazole nitrate franchise, a lower valuation, and potential ANDA […]

Adam Stormoen joins ROTH in healthcare investment banking

Adam Stormoen joins ROTH in healthcare investment banking

July 20, 2015 by · Leave a Comment 

Tweet Adam Stormoen has joined ROTH Capital Partners as a director in its healthcare investment-banking group, focusing on healthcare services and medical devices. Mr. Stormoen has more than 14 years of investment banking experience. Prior to joining ROTH, he spent five years at Dougherty & Co. where he helped build the corporate finance practice by […]

ROTH ups Titan Pharma price target to $1.50

ROTH ups Titan Pharma price target to $1.50

July 17, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on Titan Pharmaceuticals (OTCQB:TTNP) to $1.50 from $1.25. The stock closed at 80 cents on Thursday. Analyst Scott Henry writes that the driver for the increased price target is the positive Phase 3 data on Probuphine, which was reported last month. Probuphine is a six-month implant […]

Ed Arce joins Wainwright as a managing director

Ed Arce joins Wainwright as a managing director

July 9, 2015 by · Leave a Comment 

Tweet Ed Arce has joined H.C. Wainwright as a managing director in equity research and will cover companies in the biopharmaceuticals and specialty pharma sectors. He was previously a senior research analyst, covering biopharmaceuticals and specialty pharma with Roth Capital Partners. “We are excited that Ed has decided to join the biotechnology research team at […]

Roth ups BioBlast Pharma target price to $25

Roth ups BioBlast Pharma target price to $25

June 15, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for BioBlast Pharma (NASDAQ:ORPN) to $25 from $18 after the company announced plans to initiate a placebo-controlled, multi-center Phase 3 study for Cabaletta in oculopharyngeal muscular dystrophy (OPMD) in the U.S. and Canada in the third quarter this year. Shares of BioBlast closed at $5.76 on […]

Roth upgrades QLT to buy

Roth upgrades QLT to buy

June 9, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded QLT (NASDAQ:QLTI; TSX:QLT) to “buy” from “neutral” and raised its price target to $5.50 from $4.50, following the proposed acquisition of InSite Vision (OTC:INSV). The stock closed at $3.99 on Monday. “We believe that QLT’s financial resources could unlock the value in this emerging eye care company,” writes analyst […]

Next Page »

Email Newsletters with Constant Contact
Google+